In a pivotal stride to address the growing AFib epidemic, OMRON Healthcare today announced the U.S. Food and Drug ...

The FDA has granted a de novo clearance to a wearable device—with a form factor you’re familiar with—that can check patients ...

OMRON Healthcare has received de novo authorization from the U.S. Food and Drug Administration (FDA) to market new home blood pressure monitors featuring AI-powered atrial fibrillation ...

The REACT-AF trial began in July 2023 and is led by researchers at Johns Hopkins Medicine. Randomized patients (half of the ...

Boston Scientific is resuming its "Avant Guard" study of pulse field ablation (PFA) as a first-line therapy for atrial ...

Exposure to extreme heat may double or triple the risk of irregular heart rhythms in people with implanted defibrillators, ...

Choosing a fitness tracker can be intimidating, especially when starting your first fitness routine. There's a range of ...

Hello Health Rounds Readers! Today we feature a sneak peek at a trio of studies to be presented at the American Heart ...

Adding an extra hour every week of physical activity may lower the chance of developing the most common type of irregular heartbeat (arrythmia) by 11 percent, a new study shows.

Late last month, Boston Scientific announced it was pausing a study examining pulsed field ablation as a first-line therapy.

Fourth Frontier has achieved a crucial milestone with the FDA's clearance of the Frontier X Plus, a single-lead ECG monitor. Positioned to enhance heart health monitoring, this wearable device ...

Heffron notes that in the sole earlier study that used activity monitors to investigate atrial fibrillation, researchers ...